Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-22
2011-02-22
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S450000, C549S271000, C544S374000
Reexamination Certificate
active
07893068
ABSTRACT:
The present invention relates to a compound represented by the formula (I):(wherein, R3, R6, R7and R21are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.
REFERENCES:
patent: 5977109 (1999-11-01), Nakakura et al.
patent: 6712617 (2004-03-01), Detmar et al.
patent: 7026352 (2006-04-01), Mizui et al.
patent: 7256178 (2007-08-01), Kotake et al.
patent: 7550503 (2009-06-01), Kotake et al.
patent: 7576204 (2009-08-01), Nagai et al.
patent: 7619100 (2009-11-01), Kotake et al.
patent: 7667052 (2010-02-01), Mizui et al.
patent: 2003/0228404 (2003-12-01), Nishimoto et al.
patent: 2006/0009439 (2006-01-01), Kotake et al.
patent: 2006/0141589 (2006-06-01), Okuda et al.
patent: 2006/0247203 (2006-11-01), Kato et al.
patent: 2007/0155696 (2007-07-01), Ishihara et al.
patent: 2008/0021226 (2008-01-01), Kanada et al.
patent: 2008/0214564 (2008-09-01), Ishihara et al.
patent: 2008/0255146 (2008-10-01), Kotake et al.
patent: 2009/0325978 (2009-12-01), Onai et al.
patent: 1083175 (2001-03-01), None
patent: 1508570 (2005-02-01), None
patent: 1880994 (2008-01-01), None
patent: 1153092 (1969-05-01), None
patent: 45-2754 (1970-01-01), None
patent: 54-103844 (1979-08-01), None
patent: 4-352783 (1992-12-01), None
patent: 10-502616 (1998-03-01), None
patent: 2001-348384 (2001-12-01), None
patent: 2002-145885 (2002-05-01), None
patent: 2004-269488 (2004-09-01), None
patent: WO-00/75126 (2000-12-01), None
patent: WO-02/12533 (2002-02-01), None
patent: WO-02/060890 (2002-08-01), None
patent: WO-03/099813 (2003-12-01), None
patent: WO 2004/098514 (2004-11-01), None
patent: WO 2005/073223 (2005-08-01), None
patent: WO 2005/116013 (2005-12-01), None
patent: WO 2006/075690 (2006-07-01), None
patent: WO 2006/121104 (2006-11-01), None
Ryuichi Morishita. “Recent Progress in Gene Therapy for Cardiovascular Disease”, Circ Journal, vol. 66, pp. 1077-1086, (2002).
Moon-Seok Cha, “ Endogenous Production of Nitric Oxide by vascular Endothelial Growth Factor Down-Regulates Proliferation of Choriocarcinoma Cells” Biochemical and Biophysical Research Communications, vol. 282, pp. 1061-1066, (2001).
Seki-Asano, Mitsuko et al., “Isolation and Characterization of a New 12-Membered Macrolide FD-895”, J. Antibiot., 1994, vol. 47, No. 12, pp. 1395 to 1401.
Bestmann, Hans Jurgen. Synthesis, 1989, vol. 6, pp. 419-423.
Bestmann, Jans Jurgen. Angew. Chem., 1983, vol. 95, No. 10, pp. 810-811.
Furstner; Alois et al. Efficient Total Syntheses of Resin Glycosides and Analogues by Ring-Closing Olefin Metathesis, J. Am. Chem. Soc., 1999, vol. 121, pp. 7814-7821.
Gunawardana, Geewananda, et al. J. Am. Chem. Soc. 1999, vol. 121, pp. 6092-6093.
Rohr, Jurgen. Angew Chem. Int. Ed., 2000, vol. 39, No. 16, pp. 2847-2849.
Kobayashi; Jun'ichi et al. Tetrahedron Letters; 1996, vol. 37, No. 9, pp. 1449-1450.
Hamberg, Mats. LIPIDS, 2000, vol. 35, No. 4, pp. 353-363.
Hamberg, Mats. Chem. Phys. LIPIDS, 1988, vol. 46, No. 4, pp. 235-243.
Sakai et al., “Shinki ko-shuyo kassel busshitsu pladienolide ni kansuru kenkyu (1)-shinki 12-inkan macrolide pladeienolide B no tanri to kozo”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 123.
Akifumi et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (2) VEGF sansei yokusei kassei o shihyo to shita pladienolide-rui no kozo kassei sokan”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 124.
Keiji et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (3)- pladienolide-rui no yakuri kassei (in vitro, in vivo)”, Japan Society for Bioscience, Biotechnology, and Agrochemistry. Taikai Koen Yoshishu, Mar. 2003, p. 124.
Proceedings for 2003 Annual Meeting of Japan Society for Bioscience, Biotechnology, and Agrochemistry, pp. 123-124, (2003).
Ronald A. Lemahieu et al.; The Journal of Antibiotics, Jul. 1976, vol. 29, No. 7, pp. 728-734.
Roberto Spagnoli et al.; The Journal of Antibiotics, Apr. 1983, vol. 36, No. 4, pp. 365-375.
A. Anadon; Research in Veterinary Science, Jun. 1999, vol. 66, No. 3, pp. 197-203.
D.J. Farrell et al.; Journal of Antimicrobial Chemotherapy, Sep. 2002, vol. 50, Suppl., pp. 39-47.
Eskens et al., “First-in-human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) Phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors”, Abstract submission to: American Society of Clinical Oncology, date of submission: Jan. 6, 2009.
Non-Final Office Action dated Mar. 31, 2008 of U.S. Appl. No. 11/473,201.
Notice of Allowability dated Feb. 3, 2009 of U.S. Appl. No. 11/473,201.
Supplemental Notice of Allowability dated Apr. 1, 2009 of U.S. Appl. No. 11/473,201.
Supplemental Notice of Allowability dated Apr. 13, 2009 of U.S. Appl. No. 11/473,201.
Restriction Office Action dated Oct. 4, 2007 of U.S. Appl. No. 10/532,412.
Non-Final Office Action dated Feb. 6, 2008 of U.S. Appl. No. 10/532,412.
Non-Final Office Action dated Aug. 8, 2008 of U.S. Appl. No. 10/532,412.
Final Office Action dated Mar. 4, 2009 of U.S. Appl. No. 10/532,412.
Restriction Office Action dated Oct. 1, 2008 of U.S. Appl. No. 11/927,542.
Non-Final Office Action dated Feb. 11, 2009 of U.S. Appl. No. 11/927,542.
USPTO Office Action—Notice of Allowance, pp. 1-3, U.S. Appl. No. 11/927,542, Jun. 29, 2009.
USPTO Office Action—Notice of Allowability and Examiner's Amendment, pp. 1-4, U.S. Appl. No. 11/927,542, Jun. 29, 2009.
USPTO Non-Final Office Action after a Request for Continued Examination, U.S. Appl. No. 10/532,412, Sep. 15, 2009, 6 pages.
USPTO Office Action, Restriction Requirement, U.S. Appl. No. 12/021,184, Sep. 18, 2009, 7 pages.
USPTO Non-Final Office Action, U.S. Appl. No. 12/021,184, Jan. 6, 2010, 9 pages.
T. Gura, “Cancer Models: Systems for Identifying New Drugs Are Often Faulty”, Science, Nov. 7, 1997, vol. 278, No. 5340, pp. 1041-1042.
M. T. Zell, et al., “Investigation of Polymorphism in Aspartame and Neotame Using Solid-State NMR Spectroscopy,” Tetrahedron, 2000, vol. 56, pp. 6603-6616.
D. Zips, et al., “New Anticancer Agents: in Vitro and In Vivo Evaluation,” In Vivo, 2005, vol. 19, pp. 1-8.
S.L. Morissette et al., “Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization”, PNAS, Mar. 4, 2003, vol. 100, No. 5, pp. 2180-2184.
Ji Johnson, et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” British Journal of Cancer, 2001, vol. 84, No. 10, pp. 1424-1431.
J. Simone, “Part XIV—Oncology”, Textbook of Medicine, 20th Edition, W.B. Saunders Company, Feb. 3, 1997, vol. 1, pp. 1004-1010.
USPTO Office Action, Restriction Requirement, U.S. Appl. No. 11/213,962, Jun. 19, 2008, 4 pages.
USPTO Non-Final Office Action, U.S. Appl. No. 11/213,962, Oct. 9, 2008, 4 pages.
USPTO Office Action, Notice of Allowance and Notice of Allowability, U.S. Appl. No. 11/213,962, May 18, 2009, 6 pages.
USPTO Office Action, Notice of Allowance, and Notice of Allowability, U.S. Appl. No. 11/213,962, Sep. 29, 2009, 6 pages.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Aug. 4, 2009 for Application No. PCT/JP2008/051695 which corresponds to U.S. Appl. No. 60/888,257.
Kazumi Sugimori, “the Sujimori C method”, Seiyaku Koujou, vol. 6, No. 6, pp. 571-576, 1986.
Non-Final Office Action dated Jan. 9, 2006 of U.S. Appl. No. 10/515,647.
Notice of Allowance and Allowability dated Feb. 8, 2010 for U.S. Appl. No. 10/532,412.
Fukuda Yoshio
Kanada Regina Mikie
Kotake Yoshihiko
Nagai Mitsuo
Nakashima Takashi
Birch & Stewart Kolasch & Birch, LLP
EISAI R&D Management Co., Ltd.
Mercian Corporation
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Physiologically active substances does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Physiologically active substances, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Physiologically active substances will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635136